Ill address this issue in an upcoming blog on neurocognitive decline- I just went through the SGLT2-i on this series, but this is a particularly interesting area
The Critical Distinction: Herbal wellness patches marketed using "GLP-1" terminology do not contain pharmaceutical GLP-1 receptor agonists
Specifications Compound: GHK-Cu (copper tripeptide) Quantity: 100 mg per vial, lyophilized powder Purity: 99%+ HPLC standard batch-specific Certificate of Analysis included for your exact lot Identity: confirmed by LC-MS Appearance: blue lyophilized powder Documentation: Every vial ships with access to a batch-specific Certificate of Analysis showing HPLC purity, mass-spectrometry identity confirmation, endotoxin, residual solvents, and water content for your exact lot
Moreover, there are differences in laboratory assessment methods in different trials, as well as differences in intra assay coefficient of variation (intra-assay CV) and inter-assay coefficient of variation (inter-assay CV)
Dual GIP/GLP-1 agonists: tirzepatide What it is: Tirzepatide (Mounjaro) acts on both GLP-1 and GIP receptors